Adherence and outcomes: a systematic review of palivizumab utilization

References

• Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555.
   PubMed Web of Science ®Google Scholar
• Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958.
   PubMed Web of Science ®Google Scholar
• Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–546.
   PubMedGoogle Scholar
• Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917–1928.
   PubMed Web of Science ®Google Scholar
• Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res. 2014;6:217–225.
   PubMedGoogle Scholar
• Institute of Medicine (US) Committee. Appendix D-12: the prospects for immunizing against respiratory syncytial virus. In: New vaccine development establishing priorities: volume II: diseases of importance. USA: National Academies Press; 1986.
   Google Scholar
• Simões EA, DeVincenzo JP, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis. 2015;211(Suppl 1):S1–S20.
   PubMed Web of Science ®Google Scholar
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531–537.
   Google Scholar
• Sáez-Llorens X, Castaño E, Null D, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 study group. Pediatr Infect Dis J. 1998;17(9):787–791.
   PubMed Web of Science ®Google Scholar
• Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–1799.
   PubMed Web of Science ®Google Scholar
• Wegzyn C, Toh LK, Notario G, et al. Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther. 2014;3(2):133–158.
   PubMedGoogle Scholar
• Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556–569.
   PubMed Web of Science ®Google Scholar
• Shi T, Balsells E, Wastnedge E, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 2015;5(2):020416.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies: evidnce for action. (Ed.^(Eds). Geneva, Switzerland: WHO, Marketing and Dissemination. 2003.
   Google Scholar
• Hussman JM, Li A, Paes B, et al. A review of cost-effectiveness of palivizumab for respiratory syncytial virus. Expert Rev Pharmacoecon Outcomes Res. 2012;12(5):553–567.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Boonen A, Rabenda V, et al. The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res. 2012;12(2):159–166.
   PubMed Web of Science ®Google Scholar
• Bollani L, Baraldi E, Chirico G, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr. 2015;41:97.
   PubMed Web of Science ®Google Scholar
• Diseases AAoPCoI, Committee AAoPBG. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620–638.
   PubMedGoogle Scholar
• Robinson JL, Le Saux N. Canadian Paediatric Society ID, immunization C. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health. 2015;20(6):321–333.
   PubMed Web of Science ®Google Scholar
• Frogel MP, Stewart DL, Hoopes M, et al. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010;16(1):46–58.
   PubMed Web of Science ®Google Scholar
• Feltes TF, Sondheimer HM, Tulloh RM, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70(2):186–191.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Simões EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125(1):e35–51.
   PubMed Web of Science ®Google Scholar
• Fernández P, Trenholme A, Abarca K, et al. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr. 2010;10:38.
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–540.
   PubMed Web of Science ®Google Scholar
• Langkamp DL, Hlavin SM. Factors predicting compliance with palivizumab in high-risk infants. Am J Perinatol. 2001;18(6):345–352.
   PubMed Web of Science ®Google Scholar
• Oh PI, Lanctôt KL, Yoon A, et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002;21(6):512–518.
   PubMed Web of Science ®Google Scholar
• Paul DA, Leef KH, Chidekel A, et al. Home delivery of palivizumab: outcomes and compliance in regional preterm infants. Del Med J. 2002;74(1):11–15.
   PubMedGoogle Scholar
• Robbins JM, Tilford JM, Gillaspy SR, et al. Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis. Ambul Pediatr. 2002;2(6):444–448.
   PubMedGoogle Scholar
• Helm EA, Cummings GE, Keane V, et al. Administration of palivizumab: a medical provider’s perspective. Clin Pediatr (Phila). 2003;42(9):821–826.
   PubMed Web of Science ®Google Scholar
• Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J. 2004;23(4):318–322.
   PubMed Web of Science ®Google Scholar
• Macagno F, Study P (Prevenzione del Virus respiratorio sinciziale: Indagine Epidemiologica Nazionale Italiana) Investigators. Main results of a national multicenter study assessing the compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection. Pediatr Med Chir. 2005;27(3–4): 70–77.
   PubMedGoogle Scholar
• Macagno F, Study P (Prevenzione del Virus respiratorio sinciziale: Indagine Epidemiologica Nazionale Italiana) Investigators. Compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection: results of the second season of the Previeni study. Pediatr Med Chir. 2005;27(3–4): 78–87.
   PubMedGoogle Scholar
• Pignotti MS, Catarzi S, Donzelli G. A 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved? J Matern Fetal Neonatal Med. 2006;19(4):221–224.
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Bruden D, Brooks L, et al. Closer to home: local care improves compliance with RSV prophylaxis in high-risk infants. Int J Circumpolar Health. 2006;65(1):4–7.
   PubMed Web of Science ®Google Scholar
• Hand IL, Noble L, Geiss D, et al. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes. Pediatr Infect Dis J. 2008;27(2):175–176.
   PubMed Web of Science ®Google Scholar
• Thwaites R, Edwards K, Buchan S. Reducing the burden of respiratory syncytial virus: an audit of the use of palivizumab prophylaxis in the UK during the September 2001 - March 2002 RSV season. Journal of Neonatal Nursing. 2008;14(4):116–123.
   Google Scholar
• Giardino AP, Tran XG, Whitmire DA. Respiratory syncytial virus prevention outreach project. Tex Med. 2009;105(10):e1.
   PubMedGoogle Scholar
• Chang SG, Park MS, Yu JE. Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009. J Korean Med Sci. 2010;25(2):251–256.
   PubMed Web of Science ®Google Scholar
• Diehl JL, Daw JR, Coley KC, et al. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan. J Manag Care Pharm. 2010;16(1):23–31.
   PubMed Web of Science ®Google Scholar
• Hampp C, Saidi AS, Winterstein AG. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr. 2010;156(6):953–59,959.e951.
   PubMed Web of Science ®Google Scholar
• Medrano LC, García-Guereta L, Group CS. Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study. Pediatr Infect Dis J. 2010;29(12):1077–1082.
   PubMed Web of Science ®Google Scholar
• Chadha AD, Bao W, Holloway J, et al. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009. South Med J. 2012;105(8):399–404.
   PubMed Web of Science ®Google Scholar
• Bernard L, Lecomte B, Pereira B, et al. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants]. Arch Pediatr. 2015;22(2):146–153.
   PubMed Web of Science ®Google Scholar
• Escobar GJ, Gebretsadik T, Carroll K, et al. Adherence to immunoprophylaxis regimens for respiratory syncytial virus infection in insured and medicaid populations. J Pediatric Infect Dis Soc. 2013;2(3):205–214.
   PubMedGoogle Scholar
• Lundeen K, Pfeiffenberger T, Jacobson Vann J, et al. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program. J Manag Care Pharm. 2013;19(2):115–124.
   PubMed Web of Science ®Google Scholar
• Stewart DL, Ryan KJ, Seare JG, et al. Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis. BMC Infect Dis. 2013;13:334.
   PubMed Web of Science ®Google Scholar
• Banerji A, Panzov V, Young M, et al. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut. Can Respir J. 2014;21(3):185–189.
   PubMed Web of Science ®Google Scholar
• Chi H, Hsu CH, Chang JH, et al. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan. PLoS One. 2014;9(6):e100981.
   PubMed Web of Science ®Google Scholar
• Krilov LR, Masaquel AS, Weiner LB, et al. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. BMC Pediatr. 2014;14:261.
   PubMed Web of Science ®Google Scholar
• Matías I, García-García I, García-Fragoso L, et al. Palivizumab compliance by infants in Puerto Rico during the 2009-2010 respiratory syncytial virus season. J Community Health. 2014;39(6):1040–1044.
   PubMed Web of Science ®Google Scholar
• Castillo LM, Bugarin G, Arias JC, et al. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America. J Pediatr (Rio J). 2017 Feb 22;pii:S0021-7557(17)30121–3.
   Google Scholar
• Sánchez-Luna M, Medrano C, Lirio J, et al. Down syndrome as risk factor for respiratory syncytial virus hospitalization: aprospective multicenter epidemiological study. Influenza Other Respir Viruses. 2017;11(2):157–164.
   PubMed Web of Science ®Google Scholar
• Pongiglione G, Possidoni A, di Luzio Paparatti U, et al. Incidence of respiratory disease during the first two years of life in children with hemodynamically significant congenital heart disease in Italy: a retrospective study. Pediatr Cardiol. 2016;37(8):1581–1589.
   PubMed Web of Science ®Google Scholar
• Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab outcomes Study Group. Pediatr Infect Dis J. 2000;19(11):1068–1071.
   PubMed Web of Science ®Google Scholar
• Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab outcomes Registry. J Perinatol. 2008;28(7):511–517.
   PubMed Web of Science ®Google Scholar
• Simon A, Nowak H, Sterz R. Use of palivizumab in Germany: data from 2002-2007. Klin Padiatr. 2011;223(5):292–298.
   PubMed Web of Science ®Google Scholar
• Chan P, Li A, Paes B, et al. Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian Registry of Palivizumab. Pediatr Infect Dis J. 2015;34(12):e290–97.
   PubMed Web of Science ®Google Scholar
• Borecka R, Lauterbach R, Helwich E. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland. Dev Period Med. 2016;20(3):181–190.
   PubMedGoogle Scholar
• Parnes C, Guillermin J, Habersang R, et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35(6):484–489.
   PubMed Web of Science ®Google Scholar
• Wu SY, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics. 2004;114(5):e554–56.
   PubMed Web of Science ®Google Scholar
• Makari D, Checchia PA, Devincenzo J. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus. Hum Vaccin Immunother. 2014;10(3):607–614.
   PubMed Web of Science ®Google Scholar
• La Via WV, Notario GF, Yu XQ, et al. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther. 2013;26(6):666–671.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Zhao L, Mondick J, et al. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56(9):4927–4936.
   PubMed Web of Science ®Google Scholar
• Forbes ML, Kumar VR, Yogev R, et al. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Hum Vaccin Immunother. 2014;10(10):2789–2794.
   PubMed Web of Science ®Google Scholar
• Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, et al. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine. 2017;35(3):496–502.
   PubMed Web of Science ®Google Scholar
• Bont L, Checchia PA, Fauroux B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western countries. Infect Dis Ther. 2016;5(3):271–298.
   PubMed Web of Science ®Google Scholar
• Régnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J. 2013;32(8):820–826.
   PubMed Web of Science ®Google Scholar
• Zomer-Kooijker K, Van Der Ent CK, Ermers MJ, et al. Increased risk of wheeze and decreased lung function after respiratory syncytial virus infection. PLoS One. 2014;9(1):e87162.
   PubMed Web of Science ®Google Scholar
• Henderson J, Hilliard TN, Sherriff A, et al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005;16(5):386–392.
   PubMed Web of Science ®Google Scholar
• Drysdale SB, Alcazar-Paris M, Wilson T, et al. Viral lower respiratory tract infections and preterm infants’ healthcare utilisation. Eur J Pediatr. 2015;174(2):209–215.
   PubMed Web of Science ®Google Scholar
• Fauroux B, Simões EAF, Checchia PA, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 2017;6(2):173–197.
   PubMed Web of Science ®Google Scholar
• Berry CE, Billheimer D, Jenkins IC, et al. A distinct low lung function trajectory from childhood to the fourth decade of life. Am J Respir Crit Care Med. 2016;194(5):607–612.
   PubMed Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143((5 Suppl):S150–156.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Pérez-Yarza EG, García LS, et al. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants-the SPRING study. PLoS One. 2015;10(5):e0125422.
   PubMed Web of Science ®Google Scholar
• Backman K, Piippo-Savolainen E, Ollikainen H, et al. Adults face increased asthma risk after infant RSV bronchiolitis and reduced respiratory health-related quality of life after RSV pneumonia. Acta Paediatr. 2014;103(8):850–855.
   PubMed Web of Science ®Google Scholar
• Bont L, Steijn M, Van Aalderen WM, et al. Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax. 2004;59(6):512–516.
   PubMed Web of Science ®Google Scholar
• Yamin D, Jones FK, DeVincenzo JP, et al. Vaccination strategies against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2016;113(46):13239–13244.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Khan AA, Esser MT, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-Targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017;61(3): pii:e01714–16.
   PubMed Web of Science ®Google Scholar
• Villafana T, Falloon J, Griffin MP, et al. Passive and active immunization against respiratory syncytial virus for the young and old. Expert Rev Vaccines. 2017;16(7):1–13.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371(8):711–722.
   PubMed Web of Science ®Google Scholar
• Kotecha SJ, Edwards MO, Watkins WJ, et al. Effect of preterm birth on later FEV1: a systematic review and meta-analysis. Thorax. 2013;68(8):760–766.
   PubMed Web of Science ®Google Scholar
• Greenough A, Alexander J, Boit P, et al. School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants. Thorax. 2009;64(6):490–495.
   PubMed Web of Science ®Google Scholar
• Shefali-Patel D, Paris MA, Watson F, et al. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012;171(7):1055–1061.
   PubMed Web of Science ®Google Scholar
• Jorquera PA, Tripp RA. Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Rev Respir Med. 2017;11(8):609–615.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR, Kalkanoglu AE, et al. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis. 2013;207(9):1424–1432.
   PubMed Web of Science ®Google Scholar
• Colosia AD, Yang J, Hillson E, et al. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS One. 2017;12(8):e0182321.
   PubMed Web of Science ®Google Scholar
• Matias G, Taylor R, Haguinet F, et al. Estimates of hospitalization attributable to influenza and RSV in the US during 1997-2009, by age and risk status. BMC Public Health. 2017;17(1):271.
   PubMedGoogle Scholar
• Fleming DM, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15:443.
   PubMed Web of Science ®Google Scholar
• Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000181.
   Web of Science ®Google Scholar
• Chemaly RF, Torres HA, Munsell MF, et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis. 2012;206(9):1367–1371.
   PubMed Web of Science ®Google Scholar
• Molinos-Quintana A, Pérez-De Soto C, Gómez-Rosa M, et al. Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients. Bone Marrow Transplant. 2013;48(2):265–268.
   PubMed Web of Science ®Google Scholar
• Caffrey Osvald E, Clarke JR. NICE clinical guideline: bronchiolitis in children. Arch Dis Child Educ Pract Ed. 2016;101(1):46–48.
   PubMed Web of Science ®Google Scholar
• Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–1502.
   PubMed Web of Science ®Google Scholar
• Coates M, Brookes D, Kim YI, et al. Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor. Antimicrob Agents Chemother. 2017;61(9): pii:e00737–17. DOI:10.1128/AAC.00737-17
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373(21):2048–2058.
   PubMed Web of Science ®Google Scholar
• Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015;169(4):341–348.
   PubMed Web of Science ®Google Scholar
• Claydon J, Sur A, Callejas A, et al. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen. PLoS One. 2017;12(4):e0176152.
   PubMed Web of Science ®Google Scholar